Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2016 Jul;32(7):628-35.
doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

Cissy Kityo  1 , Kim Catherina Eve Sigaloff  2   3 , Tamara Sonia Boender  2   3 , Elizabeth Kaudha  1 , Joshua Kayiwa  1 , Victor Musiime  1 , Andrew Mukuye  1 , Mary Kiconco  1 , Immaculate Nankya  1 , Llilian Nakatudde-Katumba  1 , Job C J Calis  3   4 , Tobias F Rinke de Wit  2   3 , Peter N Mugyenyi  1
Affiliations
Observational Study

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

Cissy Kityo et al. AIDS Res Hum Retroviruses. 2016 Jul.

Abstract

Background: There are limited data on primary human immunodeficiency virus drug resistance (HIVDR) in pediatric populations. This study aimed to assess the prevalence of primary HIVDR and associated risk factors among children initiating first-line antiretroviral therapy (ART) in Uganda.

Methods: At three Ugandan clinics, children (age <12 years) requiring ART were recruited between January 2010 and August 2011. Before starting ART, blood was collected for viral load and pol gene sequencing. Drug resistance mutations were determined using the 2010 International AIDS Society-USA mutation list. Risk factors for HIVDR were assessed with multivariate regression analysis.

Results: Three hundred nineteen HIV-infected children with a median age of 4.9 years were enrolled. Sequencing was successful in 279 children (87.5%). HIVDR was present in 10% of all children and 15.2% of children <3 years. Nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTI (NNRTI), and dual-class resistance was present in 5.7%, 7.5%, and 3.2%, respectively. HIVDR occurred in 35.7% of prevention of mother-to-child transmission (PMTCT)-exposed children, 15.6% in children with unknown PMTCT history, and 7.7% among antiretroviral-naive children. History of PMTCT exposure [adjusted odds ratio (AOR): 2.6, 95% CI: 1.3-5.1] or unknown PMTCT status (AOR: 3.8, 95% CI: 1.1-13.5), low CD4 (AOR: 2.2, 95% CI: 1.3-3.6), current breastfeeding (AOR: 7.4, 95% CI: 2.6-21), and current maternal ART use (AOR: 6.4, 95% CI: 3.4-11.9) emerged as risk factors for primary HIVDR in multivariate analysis.

Conclusion: Pretreatment HIVDR is high, especially in children with PMTCT exposure. Protease inhibitor (PI)-based regimens are advocated by the World Health Organization, but availability in children is limited. Children with (unknown) PMTCT exposure, low CD4 count, current breastfeeding, or maternal ART need to be prioritized to receive PI-based regimens.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>
FIG. 1.
Study flowchart. ART, antiretroviral therapy.
<b>FIG. 2.</b>
FIG. 2.
Profile of specific antiretroviral drug resistance mutations detected among ART naïve and non naïve (PMTCT exposed and unknown exposure) children.
See this image and copyright information in PMC

References

    1. Chi BH, Adler MR, Bolu O, et al. : Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief. J Acquir Immune Defic Syndr 2012;60 Suppl 3:S78–S87 - PMC - PubMed
    1. Gibb DM, Giaquinto C: Children with HIV infection: Special cases. Lancet 2000;356 Suppl:s34. - PubMed
    1. World Health Organization, Unicef, UNAIDS: Global update on HIV treatment 2013: Results, impact and opportunities. WHO Bull 2013(June):7 ISBN 978 92 4 150573 4
    1. Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L: Impact of antiretroviral drugs in pregnant women and their children in Africa: HIV resistance and treatment outcomes. J Infect Dis 2013;207 Suppl 2:S93–S100 - PMC - PubMed
    1. Ton Q, Frenkel L: HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission. Curr HIV Res 2013;11:126–136 - PubMed

Publication types

MeSH terms

Substances